



*This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.*

# Revision of Precautions

## Chlorhexidine hydrochloride/ diphenhydramine salicylate/hydrocortisone acetate/benzalkonium chloride concentrated solution 50

October 17, 2017

### Non-proprietary name

Chlorhexidine hydrochloride/diphenhydramine salicylate/hydrocortisone acetate/benzalkonium chloride concentrated solution 50

### Safety measure

Precautions should be revised in the package insert.

In the Important Precautions section, the following text should be added (underlined parts are revised):

In order to predict reactions such as shock or anaphylaxis, a sufficient medical interview should be performed regarding the history of hypersensitivity to chlorhexidine preparations and for predisposition to drug hypersensitivity in advance.

The Clinically Significant Adverse Reactions subsection should be newly created in the Adverse Reactions section and the following text should be added (underlined parts are revised):

#### Shock, anaphylaxis:

Shock or anaphylaxis may occur. Patients should be carefully monitored, and if decreased blood pressure, urticaria, dyspnoea, etc. are observed, the use of this drug should be discontinued immediately and appropriate measures should be taken.